SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.
On Sept. 19, Myriad will host an in-person Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco. Paul J. Diaz, president and CEO, and other members of the Myriad executive leadership team will discuss commercialization strategies, clinical advancement and new product pipeline, and long-term financial goals.
The Morgan Stanley fireside chat will be available on Myriad’s website at investor.myriad.com. For those unable to attend Myriad’s Investor Day, the presentation and Q&A will also be available at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
| Media Contact: Glenn Farrell (385) 318-3718 PR@myriad.com | Investor Contact: Matt Scalo (801) 584-3532 IR@myriad.com |
